In its comment on draft guidance, OTC industry trade group urges US FDA to issue final guidance on "Innovative Approaches For Nonprescription Drug Products" in addition to a rule the agency has indicated would soon follow. CHPA expects that identifying information away not within a Drug Facts label that will be considered in an FDA evaluation would be determined on a case-by-case basis, with a switch NDA sponsor and the agency agreeing to terms of approval during a proposal development and review.
US FDA's recent draft guidance on on how industry can propose innovative Rx-to-OTC switches raised more questions than it answered, heightening the need for a rulemaking to clarify how sponsors can satisfy the agency's standards, says the Consumer Healthcare Products Association.
In comments submitted on the July draft guidance, the OTC industry trade group repeatedly urged the agency to publish a...